MPT0G211 is an Orally Active and Selective HDAC6 Inhibitor
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases, accounting for more than 80% of dementia cases worldwide. AD leads to the progressive loss of mental capacity and behavior, with a functional decline in the ability to learn. HDAC6 belongs to the HDAC family, and its structure contains...
ACY-1083, a Highly Selective HDAC6 Inhibitor, Reverses Chemotherapy-induced Peripheral Neuropathy
Nerves carry messages from the brain to the rest of the body. Peripheral neuropathy occurs when the peripheral nervous system is damaged. Chemotherapy-induced peripheral neuropathy is one of the most commonly and widely reported adverse side effects of cancer treatment. The symptoms of cemotherapy-induced peripheral neuropathy include pain, numbness, tingling,...